X
Pharma Advancement
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Merck to Acquire Verona

    Merck to Acquire Verona Pharma in $10B Deal Boosts COPD Drug

    Emerging Oral Small Molecule Drugs

    Emerging Oral Small-Molecule Drugs for Ultra-Rare Diseases

    FDA Approves Oral Therapy for Treating Hereditary Angioedema

    FDA Approves Oral Therapy for Treating Hereditary Angioedema

    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Merck to Acquire Verona

    Merck to Acquire Verona Pharma in $10B Deal Boosts COPD Drug

    Emerging Oral Small Molecule Drugs

    Emerging Oral Small-Molecule Drugs for Ultra-Rare Diseases

    FDA Approves Oral Therapy for Treating Hereditary Angioedema

    FDA Approves Oral Therapy for Treating Hereditary Angioedema

    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Drug Development FDA Approvals

Lynparza From AZ As Breast Cancer Cure Gets FDA Approval

Content Team by Content Team
15th March 2022
in FDA Approvals, News
Lynparza From AZ As Breast Cancer Cure Gets FDA Approval

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

The FDA approved the AstraZeneca and Merck medications for a select subset of individuals with severe early-stage breast cancer, after chemotherapy before or after surgery. The patient’s tumour must have BRCA mutations in the germline and be HER2-negative. According to the pharma partners, approximately 91 percent of all breast cancer patients in the United States are detected early, with BRCA mutations found in approximately 5% to 10% of cases. It is the first PARP inhibitor and the first targeted therapy for the post-surgery breast cancer context known as adjuvant treatment.

As per SVB Leerink analyst Andrew Berens, M.D., the ajudvant breast cancer setting could represent a $1.5 billion opportunity for Lynparza based on the patient demographic. Lynparza demonstrated its worth in the phase 3 OlympiA trial, which led to this approval. The targeted medicine lowered the chance of invasive breast cancer relapses, disease progression, or death by 42 percent when compared to placebo. Lynparza had already yielded a positive hint that it could help patients live longer when investigators presented their intrusive disease-free survival data during the plenary at the American Society of Clinical Oncology conference last year.

A new analysis has revealed that patient survival has improved in a “statistically significant and clinically meaningful” way. According to AZ and Merck, Lynparza reduced the chance of dying by 32% compared to placebo. Given that several subsequent therapies may dilute the effect, it can be challenging for cancer medications to show a considerable survival benefit in early treatment settings. Even if driving BRCA testing may be difficult, the overall survival study provides Lynparza with one powerful piece of medical evidence to persuade clinicians.

Lynparza was formerly licenced in the United States to cure BRCA-mutated metastatic breast cancer that had previously been treated with chemotherapy. The PARP inhibitor is the most frequently prescribed medicine in its class, including indications for prostate cancer, ovarian cancer, and pancreatic cancer. At constant currency rates, Lynparza earned $2.35 billion in revenues for AZ last year, up 30% from the year before that at constant currency rates. There are no company-sponsored phase 3 trials in adjuvant breast cancer for other marketed PARP inhibitors, such as GlaxoSmithKline’s Zejula, Clovis Oncology’s Rubraca, or Pfizer’s Talzenna.

Meanwhile, AZ and Merck recently announced another impressive victory for Lynparza in newly diagnosed metastatic, castration-resistant prostate cancer, illustrating that when blended with Johnson & Johnson’s Zytiga and a steroid, patients could live longer without progression of the disease regardless of their homologous recombination repair (HRR) genetic mutation status. The HRR gene panel contains BRCA genes.

Merck is also testing Lynparza with or without Roche’s Avastin as a first-line standard treatment in colorectal cancer patients who have not progressed after an induction treatment. The results of the LYNK-003 phase 3 trial are anticipated next year.

Previous Post

BioMed X Institute and Merck KGaA, Darmstadt, Germany, start second research project in immunology

Next Post

BioNTech and Regeneron Expand Strategic Collaboration to Advance Clinical Development of FixVac and Libtayo Combination in NSCLC

Related Posts

Merck to Acquire Verona
Drug Development

Merck to Acquire Verona Pharma in $10B Deal Boosts COPD Drug

21st July 2025
ChiRhoClin LogiCare3PL Partners for Drug Distribution
News

ChiRhoClin, LogiCare3PL Partners for Drug Distribution

21st July 2025
Thermo Fisher and Sanofi Partners
Manufacturing

Thermo Fisher and Sanofi Partners for US Drug Manufacturing

21st July 2025
EMA Recommendations to Secure Anti D Immunoglobulins Supply
News

EMA Recommendations to Secure Anti-D Immunoglobulins Supply

15th July 2025
FDA Approves Oral Therapy for Treating Hereditary Angioedema
FDA Approvals

FDA Approves Oral Therapy for Treating Hereditary Angioedema

15th July 2025
WuXi Biologics and Virogen Bio partner to advance VG712
News

WuXi Biologics and Virogen Bio partner to advance VG712

19th June 2025
Next Post
Evotec enters iPSC-based drug discovery partnership with Boehringer Ingelheim in ophthalmology

BioNTech and Regeneron Expand Strategic Collaboration to Advance Clinical Development of FixVac and Libtayo Combination in NSCLC

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In